Abstract Number: 931 • 2018 ACR/ARHP Annual Meeting
Patients with Seropositive Rheumatoid Arthritis Who Do Not Mount a CRP Response When They Have Synovitis Are Immunologically Distinct and Are Poorly Served By Current Management Strategies
Background/Purpose: An atypical subgroup of patients with seropositive rheumatoid arthritis (RA) has been identified with confirmed synovitis but normal levels of the acute phase protein…Abstract Number: 1017 • 2018 ACR/ARHP Annual Meeting
Autoantigen Pentraxin-3 Is an Inflammatory Cytokine Storms Suppressor By Switching Monocytes Pyroptosis to Apoptosis in a Complement-Dependent Manner in Rheumatoid Arthritis
Background/Purpose: A delayed diagnoses and therapy of ACPA (Anti cyclic citrullinated peptide antibody)-negative RA patients might be associated with effective serum biomarkers in clinic. Methods:…Abstract Number: 1098 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are autoimmune diseases. The histopathological pattern of skin involvement can be similar, i.e. interface dermatitis, but the…Abstract Number: 1708 • 2018 ACR/ARHP Annual Meeting
Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus
Background/Purpose: Although aberrant complement activation is involved in the pathogenesis of systemic lupus erythematosus (SLE), the role of complement regulatory proteins in disease activity of…Abstract Number: 670 • 2017 ACR/ARHP Annual Meeting
Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment
Background/Purpose: LN is characterized by deposition of immune complexes in the kidney. Activation of the classical complement pathway by dsDNA is believed to play a…Abstract Number: 1077 • 2017 ACR/ARHP Annual Meeting
The Lectin Pathway of the Complement System Is Activated in Patients with Systemic Lupus Erythematosus
Background/Purpose: The pathogenesis of Systemic Lupus Erythematosus (SLE) involves complement activation. It is well established that activation of complement through the classical pathway (CP) and…Abstract Number: 1671 • 2017 ACR/ARHP Annual Meeting
Complement C4 Gene Copy Number Variations Bestow Large Ranges of Serum C4 Protein Levels in Chinese Patients with Systemic Lupus Erythematosus (SLE) and Contribute to Organ and Cardiovascular Damages over Time
Background/Purpose: Human SLE is characterized by fluctuating serum levels of complement proteins. There are frequent copy number variations (CNVs) of complement C4A and C4B genes…Abstract Number: 1842 • 2017 ACR/ARHP Annual Meeting
Subsetting Systemic Lupus Erythematosus By Interferon Gene Signatures and Serologies (anti-dsDNA and Low Complement) Uncovers Significant Clinical Diversity
Background/Purpose: Personalized therapy in systemic lupus erythematosus (SLE) will require identifying SLE subsets that will benefit from different targeted therapies. Belimumab, for example, has…Abstract Number: 129 • 2017 Pediatric Rheumatology Symposium
Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…Abstract Number: 149 • 2017 Pediatric Rheumatology Symposium
Deficiency of Complement C4A or Low Copy Number of Total C4 Genes, HLA-DRB1*15 and HLA-DRB1*03 Are Strong Genetic Risk Factors for Pediatric SLE of European Descent
Background/Purpose: A complete genetic deficiency of complement C4 almost always leads to the pathogenesis of systemic lupus erythematosus (SLE) with childhood onset, although its prevalence…Abstract Number: 1751 • 2016 ACR/ARHP Annual Meeting
Coagulation Pathway Function in Ischemia/Reperfusion Tissue Injury in Autoimmune Prone Mice
Results: Tissue Factor Pathway Inhibitor (TFPI) and Anti-thrombin III (ATIII) resulted in reduction of tissue injury, as determined by histopathology scoring. However, TFPI was significantly…Abstract Number: 2421 • 2016 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products Correlate with Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…Abstract Number: 2797 • 2016 ACR/ARHP Annual Meeting
Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus
Background/Purpose: A panel of autoantibodies in combination with C4d-bound complement activation products (CB-CAPs, EC4d and BC4d) has been established as a sensitive and specific testing…Abstract Number: 2856 • 2016 ACR/ARHP Annual Meeting
Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms
Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…Abstract Number: 2958 • 2016 ACR/ARHP Annual Meeting
Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden
Background/Purpose: Since first described by McDuffie et al. in 1973, hypocomplementemic urticarial vasculitis (HUV) syndrome has been recognized as a specific autoimmune disorder involving at…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- Next Page »